Avior Wealth Management LLC Grows Stake in Repligen Co. (NASDAQ:RGEN)

Avior Wealth Management LLC increased its holdings in shares of Repligen Co. (NASDAQ:RGEN) by 22.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,123 shares of the biotechnology company’s stock after purchasing an additional 384 shares during the quarter. Avior Wealth Management LLC’s holdings in Repligen were worth $382,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Invesco Ltd. grew its position in shares of Repligen by 3.9% during the first quarter. Invesco Ltd. now owns 1,756,157 shares of the biotechnology company’s stock worth $330,315,000 after purchasing an additional 65,550 shares in the last quarter. State Street Corp grew its holdings in Repligen by 0.9% during the 2nd quarter. State Street Corp now owns 1,651,310 shares of the biotechnology company’s stock valued at $233,594,000 after buying an additional 14,647 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in Repligen by 11.3% during the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company’s stock valued at $247,558,000 after buying an additional 157,807 shares in the last quarter. Wellington Management Group LLP grew its holdings in Repligen by 2.1% during the 3rd quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company’s stock valued at $222,075,000 after buying an additional 29,215 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in Repligen by 13.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company’s stock valued at $190,117,000 after buying an additional 137,220 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

Shares of RGEN stock opened at $157.06 on Friday. Repligen Co. has a 52-week low of $110.45 and a 52-week high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.75 and a current ratio of 7.02. The firm has a market capitalization of $8.77 billion, a P/E ratio of 218.14, a P/E/G ratio of 5.27 and a beta of 1.02. The stock has a 50 day moving average price of $190.02 and a 200 day moving average price of $173.20.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a return on equity of 5.00% and a net margin of 6.51%. The firm had revenue of $155.74 million during the quarter, compared to analyst estimates of $155.38 million. During the same period last year, the company earned $0.68 EPS. Repligen’s quarterly revenue was down 16.6% compared to the same quarter last year. As a group, sell-side analysts predict that Repligen Co. will post 1.46 earnings per share for the current year.

Analysts Set New Price Targets

RGEN has been the subject of several research analyst reports. KeyCorp raised their price target on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Thursday, February 15th. Stifel Nicolaus raised their price target on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $196.70.

Insider Buying and Selling

In related news, CEO Anthony Hunt sold 16,707 shares of the firm’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $197.44, for a total transaction of $3,298,630.08. Following the completion of the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at approximately $36,575,562.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the sale, the vice president now directly owns 24,260 shares of the company’s stock, valued at approximately $4,699,889.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Anthony Hunt sold 16,707 shares of Repligen stock in a transaction on Friday, March 8th. The shares were sold at an average price of $197.44, for a total value of $3,298,630.08. Following the sale, the chief executive officer now directly owns 185,249 shares of the company’s stock, valued at $36,575,562.56. The disclosure for this sale can be found here. In the last three months, insiders sold 25,597 shares of company stock valued at $5,039,532. Insiders own 1.20% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.